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Abstract






Chronic diseases and their management are high on the agenda of European and North American healthcare reforms. This agenda is most often associated with the transformation of healthcare system towards more integration, particularly between primary care and specialized 'platforms' of care, with the aim to optimize outcomes while putting patients at the centre of the management process. To achieve this aim, policy-makers revise legislation for new functions [e.g. case management, advanced nurse practice], revise payment systems, favour inter-organizational and inter-professional governance structures, and facilitate information exchange through shared clinical data.
The process of such reforms often starts with the most common diseases, such as diabetes and hypertension, particularly if associated with co-morbidities. However, there are other chronic diseases for which profound upheavals of management are taking place. This is the case for Crohn's disease [CD]. Higher patient involvement and personalized medicines come as a natural response to the key management challenges of CD as with other chronic diseases. However, expected interactions between primary care providers, CD specialists and patients may be specific. In such situations, complex decisions relying on multiple dimensions and involving several stakeholders cannot be based only on classical guidelines implemented through the clinician's intuition. We propose that these challenges could be addressed through a shared clinical file, connected via a clinical decision support system [CDSS]. This may be adapted in particular to help decide when to start and when to stop immunomodulators, biological therapies and/or new small molecules in CD.
The objective of this paper is to present arguments to develop such integrated information management systems in helping to make tailored decisions for individual patients.
2. Key challenges for the management of CD
CD shares three important features with other relatively infrequent chronic diseases [Figure 1]. These features make the management of such disease difficult.
Firstly, CD is not a frequent disease. Its prevalence in 2013 was around 10:10 000 in European countries, not far above the threshold [5:10000] to be considered as a rare disease.1,2 However, incidence and prevalence have been on the rise, although unequally across countries, between 1995 and 2010 with a north-south, east-west and urban-rural gradient.3 Therefore, it should no longer be considered as rare. CD is also responsible for a substantial level of disability in young people, leading to substantial loss of disability-adjusted life years [DALY] and strong psychosocial burden.4 Despite the continuous increase in prevalence of CD, the number of cases taken care of by general practitioners [GPs] is still relatively low and its management remains difficult to master by the primary healthcare providers. Hence, it requires an optimal collaboration between GPs and gastroenterologists (GE).

Figure 1. Illustration of the needs, coherence and potential tensions linked to the management of chronic disease, with Crohn's disease as an example.


Secondly, the best current medical strategies to treat CD raise questions about their safety and cost. Recent trials favoured biological treatments to treat moderate to severe immune-mediated inflammatory disorders [IMIDs] such as CD.5-9 In 2010, the SONIC trial changed the treatment paradigm in CD with the emergence of the combination of anti-tumour necrosis factor [anti-TNF] + immunomodulator [combo-therapy] to treat moderate to severe forms of CD.10-12 However, the implementation of combo-therapy may carry some specific risks [risk of non-Hodgkin's lymphoma, skin cancers, serious or opportunistic infections] that may counterbalance the clinical benefits, particularly in some patient categories.13-17 On the other hand, biologicals are amongst the most expensive for healthcare systems and over the last 10-15 years, many countries have seen a substantial increase in the cost per capita of treatments with biologicals: in western countries they may now represent the majority of the cost of CD management.18,19 Incremental cost-effectiveness ratios [ICERs] based on Markov decision-making models suggest that the cost-efficiency of anti-TNF agents is mainly favourable for a duration of use not exceeding 4 years, as well as for patients who have had no prior treatment with biologicals. Maintenance of long-term remission may not represent acceptable cost-effectiveness, particularly when the most expensive biologicals are considered.20,21 These models may favourably be impacted by the lower the prices associated with biosimilars. The decision to start, optimize or stop therapy in CD is complex and multifactorial and requires the integration of a large number of factors.
Thirdly, the course of CD [with sequences of relapses—to be controlled—and remission—to maintain] is particularly complex and difficult to predict. Progression of the disease depends on several demographic and clinical characteristics including age at diagnosis, disease location and type of lesions.23 Echoing this variability, several treatment strategies have been proposed focusing on the start, optimization and withdrawal of immunomodulators and/or biological treatments.22 These strategies have their own risks and benefits and are guided by patient profiles, patients' and physicians' preferences and cost issues, with different rules across western countries.22-25 Given the heterogeneity of CD, the need to avoid intestinal damage and disability, and the different treatment strategies available, a 'treat to target' approach has been proposed with the aim to reach full control of the symptoms in the form of patient-reported outcome measures [PROMs] as well as intestinal healing in order to block progression towards bowel damage and disability.26 This represents a way of adopting personalized medicine for CD. A recent meta-analysis on personalized medicine showed encouraging results, if the determinants—to customize the treatment—are well identified.27 To be able to formally develop a personalized medicine in CD, based on the 'treat to target' concept, monitoring tools are needed. Gold standards are endoscopy and cross-sectional imaging. However, to limit invasiveness and costs, bio-markers are being actively explored. These markers include blood and stool markers of inflammation as well as blood drug levels. The purpose is to have continuous information on the patient's condition and to implement monitoring to detect inappropriate disease control and the risk of disease progression or relapse within a period, allowing rapid therapeutic readjustment as recently illustrated in the CALM trial.24 This monitoring with objective markers has to be integrated with other outcome measures including PROMs. 
3. Specific needs relating to chronic disease health management
While the nature of CD itself makes it difficult to manage, some specific needs relating to chronic health management must also be taken into account to achieve optimal outcomes.
3.1. Need to reflect on the value of health in the management of chronic disease
CD allows the opportunity to highlight different conceptions of what is 'health' and what could be the priorities for different stakeholders. These differences are materialized in terms of indicators or criteria of health, and in terms of time frame. The patient's health goals [which should be protected by primary care providers] fit into all dimensions of the quality of his or her life and during the whole course of life with the disease. The GE must have individual and instantaneous physiological indicators reflecting the ongoing inflammation and its consequences [tissue damage]. Policy-makers must have a mix of individual and population criteria ensuring sustainability of the system of health care for the community at large. In this sense, it is appropriate to build a framework centred on the patient, simultaneously integrating all these complementary dimensions of the patient's health.
3.2. Need to move from planned and controlled care to adaptive patient-centred care
Medicine, strictly evidence-based, implies a model of standardized, planned and controlled therapeutic strategies, with a predicted outcome of health in a majority of cases. This predictive medicine may be limited complex chronic diseases such CD, where it is imperative to contextualize for any patient—at any time—the evidence provided by medical research in the field. Support of CD patients must be more flexible, more nuanced, more dynamic and less crystallized in evidence-based medicine, while using the state-of-the-art. We could define it as an Adaptive care, to meet the health needs of each patient. This form of medicine needs instantaneous access to multiple data points related to the state of the patient, the patient's expectations and the state of knowledge.
Physicians can perceive an objective necessity to revise a therapeutic strategy when confronted with the results of monitoring with biomarkers. However, the patient has to play a central role for 'success' in the management of his or her disease. Recently, integrating telemedicine into the management of the patient to monitor and register disease activity resulted in fewer GE visits and less frequent hospitalization, while not decreasing quality of life.28 Beyond this monitoring of the disease by the patient, adaptive patient-centred care also raises the issue of the preferences, priorities and needs of the patient, after having provided them with exhaustive information on all possible strategies to manage CD.29
3.3. Need to reposition primary care and organize levels of care
It has become mainstream to give a more central position to primary care. This is a recurring desire expressed by all public health systems, through different reports, guidelines, and relating to various diagnoses.30 This would mean transferring care usually provided by specialists to the GP. We could easily conceive that after the adoption of a specific therapeutic strategy for CD by the GE, a part of the monitoring and/or follow-up could be transferred to the GP.
However, given the low frequency of CD, GPs do not have the opportunity to develop the experience and skills to ensure appropriate follow-up, nor do they have the tools to forge this experience. This even starts with diagnosing the disease: it is often delayed, which results in more complications and surgical resections.31 As for rare diseases, CD patients can be 'specialists of their illness', knowing more on particular aspects than the GP. In such situations, CD patients may prefer to seek advice from a GE. A supplementary level of care should even be added in some circumstances: due to increasing complexity in CD care, more patients are referred from a community GE to a highly specialized GE [sometimes in tertiary referral centres]. It is unlikely that these highly specialized GEs will have the ability to provide complete follow up of the patients in the context of tight monitoring with both objective markers and PROMs, and of implementation of preventive measures required for some CD therapies. New forms of 'shared care' between the patient and the different levels of care will therefore be needed, including the definition of each actor's role and ensuring the availability of guidance tools and access to the opinion of experts.32 This would also be of a great help in situations where the patients have to move frequently for social or professional reasons. In this setting the role of the patients is also very important, and patient education is mandatory to allow them to appropriately contribute to the quality of the care they receive. This shared care centred on the patient and including constant input from a highly specialized GE should minimize the use of inappropriate strategies and missed opportunities in the management of CD, also minimizing the risk of cumulated tissue damage, disability or even death, and allowing us to reduce the global burden and costs linked to CD.
4. A comprehensive strategy for integrated CD management: a shared clinical file coupled with CDSS
The usual forms of regulation strategies for CD are based on 'classical guidelines' and/or specific modalities of reimbursement. However, given the evolution of CD management and all the issues mentioned above, we believe that new modalities for regulation need to be proposed. In particular, CD requires the adoption of a more comprehensive and longitudinal view of the patient.
We hypothesize that a combination of a shared clinical file with a CDSS may become important in regulating the management of CD. A CDSS was defined in 2005 as any electronic system that aims to assist clinical decision-making through the process of individual health data, to make assessments and recommendations for caregivers.33 This is a part of new tools to aid in therapeutic decision-making, such as adaptive and customized artificial intelligence tools, which are set to become the standard.34,35 These tools should be able to respond to the increasingly complex findings of research in the area of CD management.36 They are also necessary for monitoring of the patient [including different indicators related to various dimensions of the health of the patient] and to create a channel of communication between primary care, the medical specialist and the patient for better sharing of knowledge. These types of tools should clearly be integrated into the patient's electronic medical record.37
In many areas, the implementation of a CDSS has proved effective in improving the quality of practice, in providing more personalized care [tailored] and improving health outcomes.33,38,39
Furthermore, when guidelines are integrated into a CDSS, there was an improvement in compliance/adherence to guidelines for practitioners and less redundancy.35,40
Beyond the usual outcomes focused on estimation of the patient's health [in terms of quality or efficiency], the CDSS should hold details on the quality of patient care and safety, such as patient reported outcomes [PROs: reports of patients about their health, quality of life or functional status], PROMs [PROs reported with tools/instruments] or patient-reported experience measures [PREMs: satisfaction scales providing insight into the patient's experience with their care or health service] .41,42 In some countries and healthcare systems where electronic medical records are not widely used, this would represent a huge challenge and would require a multiple steps of evolution and reform.
5. Three modules to ensure high-quality care and to foster effective research in CD
The CDSS dedicated to CD [CDSS-CD] may consist of three inter-operative modules [Figure 2]. A first decision support module would incorporate three sources of data: monitoring data [patient's individual characteristics, history of the disease, monitoring results]; algorithms for treatment strategies [using a knowledge base—an algorithm derived from published evidence—with an inference engine that will on the one hand use patient data, and on the other rely on computer learning to analyse clinical data to enhance the validity of the algorithm]; and quality monitoring guidelines [guidelines to monitor the quality of care including safety, effectiveness and continuity of care].
A patient-centred collaborative practice module would be the interface accessible to stakeholders as the foundation for the health practitioner's collaboration around the patient, allowing each caregiver to have information provided by the others as a general overview of the patient's current state. In this regard, one group has been working on and aims to optimize such a platform for the care of patients with inflammatory bowel disease.43

Figure 2. The Crohn's disease clinical decision support system [CDSS-CD] encompasses three modules: decision support, patient-centred collaborative practice and data aggregation.The central part is the key tool that will integrate stakeholders' views and help the healthcare practitioner to make a decision tailored to the patient and the system in which he or she is working. The decision is helped by the decision support tool. The module will also generate a large amount of real-life data [data aggregation] useful for effectiveness research. CER: comparative effectiveness research.

As a final step, the third module related to data aggregation would enhance population-based knowledge as real-world data collection may allow new research designs relating to treatments and processes of care. Indeed, this kind of tool may not only improve decisionmaking in complex situations for individual CD patients but also serve as a base for ongoing 'real-life data' research. For example, controversies on the cost-effectiveness of the biological treatments given to maintain remission remain unresolved and long-term risks have yet to be estimated. The electronic health data continuously recorded from CD patients may allow for the future exploration of these issues via the design of studies based on 'real-world health data'. Analytical methods related to 'comparative effectiveness research' can improve the validity of the results from non-randomized samples [using proxy-variables via propensity scores, cross-over designs to analyse variability within patients treated successively with different drugs, instrumental variables to control inter-prescriptors variation, etc.].44,45 'Hybrid effectiveness-implementation' design may allow us to assess both the impact on health and the results of implementing the therapeutic scheme.46 Assessing risk in the medium and long term can be mapped for each strategy [hospitalizations, surgeries, etc.]. An estimate of the cost-effectiveness [using, for example, Markov models] of each therapeutic strategy may also be carried out and stratified in all situations and types of pathology.
6. Conclusion
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